Atai Beckley N.V.

NasdaqGM:ATAI Stock Report

Market Cap: US$960.2m

Atai Beckley Balance Sheet Health

Financial Health criteria checks 5/6

Atai Beckley has a total shareholder equity of $143.9M and total debt of $8.7M, which brings its debt-to-equity ratio to 6%. Its total assets and total liabilities are $189.2M and $45.3M respectively.

Key information

6.02%

Debt to equity ratio

US$8.66m

Debt

Interest coverage ration/a
CashUS$95.94m
EquityUS$143.93m
Total liabilitiesUS$45.28m
Total assetsUS$189.20m

Recent financial health updates

Recent updates

Atai Life Sciences: Still A Decent Prospect - But Only Just

Oct 01

Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

May 16
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt

Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating

Apr 21

Atai: Following The Path That Spravato Laid And Moving Beyond It

Feb 27

Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst

Jan 29

Psychedelic Stock Deep Dive: Atai Life Sciences

Sep 03

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

Jul 15
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?

ATAI: Enormous Potential Upside But No Clarity Yet

May 27

Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

Mar 02
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?

atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug

Oct 12

Atai Life Sciences: Decentralized Drug Discovery Platform

Oct 06

ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01

Aug 15

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Aug 07
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer

Jul 07

atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO

Jun 30

Atai Life Sciences N.V.: A First Take

Jun 02

Atai Life Sciences And The Future Of Psychedelics For Mental Health

May 27

We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Apr 22
We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely

Financial Position Analysis

Short Term Liabilities: ATAI's short term assets ($102.7M) exceed its short term liabilities ($25.5M).

Long Term Liabilities: ATAI's short term assets ($102.7M) exceed its long term liabilities ($19.7M).


Debt to Equity History and Analysis

Debt Level: ATAI has more cash than its total debt.

Reducing Debt: ATAI's debt to equity ratio has increased from 1.5% to 6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATAI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ATAI is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/06 07:56
End of Day Share Price 2025/11/06 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atai Beckley N.V. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation
Harry GillisBerenberg
Sumant Satchidanand KulkarniCanaccord Genuity